Navigation Links
MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock
Date:8/29/2012

MOUNTAIN VIEW, Calif., Aug. 29, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the underwriter of its recent public offering of common stock fully exercised its option to purchase an additional 582,088 shares of common stock. The issuance of the additional shares has closed, and all of the shares were sold by MAP Pharmaceuticals. The total gross proceeds of the offering (including the proceeds from the offering and the exercise of the option) were approximately $59.8 million, and the total net proceeds were approximately $56.2 million, after deducting underwriting discounts and commissions. MAP Pharmaceuticals intends to use the proceeds from the offering for general corporate purposes and commercialization activities for LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. 

BofA Merrill Lynch acted as the sole book-running manager for the offering. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine.

Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as how MAP Pharmaceuticals intends to use the net proceeds from the offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to the impact of general economic, industry or political conditions in the United States or internationally. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to MAP Pharmaceuticals and our business can be found under the heading "Risk Factors" in our most recent Form 10-Q filed with the SEC, in other filings that we periodically make with the SEC, and in the prospectus supplement related to the offering filed with the SEC on August 1, 2012. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: Christopher Y. Chai, Sr. Vice President and Chief Financial Officer of MAP Pharmaceuticals, Inc., (650) 386-3107; or media, Lisa Borland, (650) 386-3122, lborland@mappharma.com.

Copyright (C) 2012 PR Newswire. All rights reserved


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Today Stock-Callers.com have issued ... are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards ... SSH ). These companies are part of the Healthcare ... Thursday, March 23 rd , 2017, with the NYSE Health ... health care companies in the S&P 500 were down about ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, a ... medical technology for non-invasive surgery, announced today CE ... for treatment of uterine fibroids throughout the European ... received approval from the US Food and Drug ... Mirabilis System in the United States.  The Mirabilis ...
(Date:3/23/2017)... Care, based in St. Joseph, Missouri , has selected AccuReg to ... located in 22 cities, and its flagship St. Joseph Medical Center. Mosaic ... health care to its patients, including the insurance, billing and collections processes. ... ... Care St. Joseph Medical Center ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Texas ... which can be found at 9618 Huebner Road. The clinic is the group’s 7th ... Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, which ...
(Date:3/24/2017)... Arizona (PRWEB) , ... March 24, 2017 , ... ... Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during the ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... they are now offering treatments for sleep apnea and TMJ at their office. ... Sleep apnea , specifically the obstructive type, is increasingly being treated at dental ...
(Date:3/24/2017)... ... 2017 , ... Viewers who like to educate themselves on current issues and ... services, and societal issues tend to appreciate and love the "Informed" series, hosted by ... running events for causes around the world. , Running for charity has ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner of Serenity ... MD. Judy says, “I am passionate about sharing Reiki as a holistic, complementary ... and challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys ...
Breaking Medicine News(10 mins):